# NAMPT inhibitor payloads

Source: https://onco.cc/terms/nampt-inhibitor-payloads/  
OnCo record `nampt-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads cut off a supply route for a molecule cells need to keep their metabolism working. Antibody delivery is being studied to direct that effect toward tumors.

## Summary

NAMPT inhibitors interfere with nicotinamide adenine dinucleotide, or NAD, salvage. Anti-c-KIT conjugates showed target-dependent efficacy in a gastrointestinal stromal tumor xenograft study. A later primary study examined physicochemical and metabolic optimization of NAMPT inhibitor conjugates for blood and solid tumor models. These are preclinical payload studies; the dependence of healthy tissues on NAD makes selective delivery and tolerability central questions.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: NAD depletion payloads; nicotinamide phosphoribosyltransferase inhibitor payloads

## Sources

- Karpov et al., NAMPT inhibitors as conjugate payloads (2018): https://doi.org/10.1021/acsmedchemlett.8b00254
- Ruedas et al., NAMPT payload optimization (2026): https://doi.org/10.1021/acsbiomedchemau.6c00047

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/nampt-inhibitor-payloads.json